Using polymeric nanoparticles to systemically deliver CT20p, we achieved regression of breast and prostate tumors in mice (74–76) and demonstrated that CT20p directly binds to the CCT2 subunit (42). This evidence concerns the gene CCT2 and prostate neoplasm.